Cadrenal Therapeutics, Inc. (CVKD) to Raise $7 Million in IPO
Cadrenal Therapeutics, Inc. (CVKD) to Raise $7 Million in IPO
Cadrenal Therapeutics, Inc. (CVKD) is planning to raise $7 million in an initial public offering (IPO) on Friday, December 16th, IPO Scoop reports. The company will be issuing 1,400,000 shares at $5.00 per share.
IPO Scoop报道，Cadrenal Therapeutics, Inc.（CVKD）计划在12月16日星期五的首次公开募股（IPO）中筹集700万美元。该公司将以每股5.00美元的价格发行140万股股票。
Cadrenal Therapeutics, Inc. has a market-cap of $55.6 million.
Cadenaral Therapeutics, Inc.的市值为5,560万美元。
Boustead Securities and Sutter Securities acted as the underwriters for the IPO.
Boustead Securities和萨特证券担任首次公开募股的承销商。
Cadrenal Therapeutics, Inc. provided the following description of their company for its IPO: "(Note: Cadrenal Therapeutics, Inc. added Sutter Securities as a joint book-runner with Boustead Securities (previously sole book-runner) in an S-1/A filing dated Dec. 8, 2022. Previously: Cadrenal Therapeutics cut the size of its IPO in an S-1/A filing dated Dec. 6, 2022, to 1.4 million shares – down from 2 million shares – at $5.00 each to raise $7.0 million. This downsizing represents a 30 percent cut in the deal's size, in terms of estimated IPO proceeds. The company is offering all 1.4 million shares in the IPO. (**Note: Selling stockholders have registered to offer 1.7 million shares (1,704,783 shares) of common stock to be sold pursuant to a separate resale prospectus. We will not receive any proceeds from the sale of the common stock to be sold by the Selling Stockholders.) We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. We secured the rights to tecarfarin on April 1, 2022, via an asset purchase agreement from HESP LLC, a wholly owned subsidiary of Horizon Technology Finance Corp., which in turn had bought tecarfarin and the other assets of Espero Biopharma, Inc. We intend to complete the clinical development of tecarfarin and seek FDA approval for the drug. We intend to initiate our pivotal Phase 3 clinical trial in the second half of 2023, subject to completion of this offering and funding from additional financings, which we believe will be our remaining pivotal trial based upon the latest feedback that the prior owner of tecarfarin had with FDA in 2019. We have licensed out the rights to tecarfarin for several Asian markets, including China, to Lee's Pharmaceutical Holdings Limited, an integrated research-driven and market-oriented biopharmaceutical publicly listed company based in Hong Kong with over 25 years' experience in the pharmaceutical industry in China. Lee's Pharmaceutical Holdings Limited is developing tecarfarin as an anti-thrombotic for patients with mechanical heart valves. In 2020 and 2021, Lee's Pharmaceutical Holdings Limited completed two Phase 1 studies in China and Hong Kong; the company is currently preparing for its Phase 2 trial. Note: Revenue (zero) and net loss figures are from the date of inception on Jan. 25, 2022, through June 30, 2022. (Note: Cadrenal Therapeutics, Inc. filed its S-1 on Sept. 22, 2022; it submitted a confidential filing on July 15, 2022.) ".
Cadrenal Therapeutics, Inc. 在2022年12月8日的S-1/A文件中将其公司的首次公开募股描述如下：“（注意：Cadrenal Therapeutics, Inc.将萨特证券列为联席账簿管理人，与Boustead Securities（前身为唯一账簿管理人）。此前：Cadrenal Therapeutics在2022年12月6日的S-1/A文件中将其首次公开募股的规模从200万股削减至140万股，每股5.00美元，筹集了700万美元。就估计的首次公开募股收益而言，此次缩减规模意味着该交易的规模缩减了30％。该公司将在首次公开募股中发行全部140万股股票。（**注意：根据单独的转售招股说明书，卖出股东已登记发行170万股（1,704,783股）普通股，待出售。我们不会从出售普通股中获得任何收益，供卖出股东出售。）我们专注于开发替卡法林，这是一种具有孤儿药适应症的新疗法，旨在预防终末期肾脏疾病（ESRD）和房颤（心跳不规则）（aFib）患者的心源性全身性血栓栓塞（血块）。我们于2022年4月1日通过Horizon Technology Finance Corp. 的全资子公司HESP LLC的资产购买协议获得了替卡法林的权利，后者反过来收购了替卡法林和Espero Biopharma, Inc.的其他资产。我们打算完成替卡法林的临床开发并寻求美国食品药品管理局对该药物的批准。我们打算在2023年下半年启动关键的3期临床试验，前提是本次发行的完成以及额外融资的资金。根据替卡法林的前所有者在2019年向FDA获得的最新反馈，我们认为这将是我们剩下的关键试验。我们已将包括中国在内的多个亚洲市场的替卡法林版权授权给李氏制药控股有限公司。李氏制药控股有限公司是一家以研究为导向、以市场为导向的综合生物制药上市公司，总部位于香港，在中国制药行业拥有超过25年的经验。李氏制药控股有限公司正在开发替卡法林作为机械性心脏瓣膜患者的抗血栓药。2020年和2021年，李氏制药控股有限公司在中国和香港完成了两项1期研究；该公司目前正在为其2期试验做准备。注意：收入（零）和净亏损数字从2022年1月25日开始之日起至2022年6月30日。（注意：Cadrenal Therapeutics, Inc. 于2022年9月22日提交了S-1；它于2022年7月15日提交了一份机密文件。）”
Cadrenal Therapeutics, Inc. was founded in 2022 and has 4 employees. The company is located at 822 A1A North, Suite 320 Ponte Vedra, Florida 32082 and can be reached via phone at (904) 300-0701 or on the web at
Cadenary Therapeutics, Inc. 成立于 2022 年，拥有 4 名员工。该公司位于 A1A North 822，320 套房，Ponte Vedra，佛罗里达州 32082，可以通过电话 (904) 300-0701 或在网上拨打以下地址与该公司联系
Receive News & Ratings for Cadrenal Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Cadenary Therapeutics Inc. 的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Cadrenal Therapeutics Inc.及相关公司的最新新闻和分析师评级的简明每日摘要。